Whatever the final outcome of the legal battle that has been going on between Nidek Co. and VISX Inc. for nearly 4 years, it is clear that those on the sidelines want such a contest never again to create such a burden for ophthalmologists.
ChatGPT may have a future use in glaucoma
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
Therapeutic in development to take on diabetic macular edema
Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410
Stress resilience–enhancing drugs: New class of small molecules holds promise